NCT05922813View on ClinicalTrials.gov

Evaluate the Safety and Tolerability of a Single-dose Administration of BMI2004 Inj.

PHASE1CompletedINTERVENTIONAL

Enrollment

257

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

March 10, 2023

Study Completion Date

April 12, 2023

Conditions

Health, Subjective

Interventions

BIOLOGICAL

BMI2004

hyaluronidase, recombinant

OTHER

0.9% NaCl

Normal Saline

Trial Locations (1)

06973

Chung-Ang University Hospital, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

BMI Korea

INDUSTRY